METHOD FOR PREDICTING RISK OF DEATH IN HOSPITALIZED PATIENTS WITH COVID-19 RECEIVING RENAL REPLACEMENT THERAPY WITH PROGRAMMED HAEMODIALYSIS FOR STAGE 5 CHRONIC KIDNEY DISEASE Russian patent published in 2024 - IPC G01N33/49 G01N33/68 A61B5/00 A61B8/13 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to nephrology, infectology, internal diseases, and can be used to predict the risk of death in hospitalized patients with COVID-19, receiving renal replacement therapy with programmed haemodialysis for chronic kidney disease stage 5. Blood neutrophil-leukocyte ratio, lactate dehydrogenase (LDH), as well as X-ray signs and comorbidity are assessed. Points are assigned to each of the listed features: neutrophil-leukocyte ratio of more than 11.9 – 8 points, C-reactive protein (CRP) more than 60 mg/l – 6 points, LDH more than 330 units/l – 5 points, creatine phosphokinase (CPK) more than 208 units/l – 4 points, interleukin-6 (IL-6) more than 60 pg/ml – 2 points, D-dimer more than 1.57 mcg/ml – 2 points, ferritin more than 2,008 mcg/l – 2 points, female sex – 2 points, age over 76 years – 3 points, diabetes mellitus – 2 points, obesity – 2 points, introductory period to haemodialysis – 3 months from the start of renal replacement therapy – 2 points, 2nd degree of lung involvement on CT or Rg – 2 points, higher than 2nd degree of lung involvement on CT or Rg – 5 points. If total score is 20 points and more, lethal outcome is predicted.

EFFECT: method enables the effective prediction of the lethal outcome in hospitalized patients with COVID-19 receiving renal replacement therapy with programmed haemodialysis for stage 5 chronic kidney disease by scoring the patients taking into account the neutrophilic-leukocyte ratio, blood LDH, CRP, CPK, IL-6, D-dimer, ferritin, as well as X-ray signs and comorbidity.

1 cl, 3 tbl, 2 ex